Neither Cytochrome P450 Family Genes nor Neuroendocrine Factors could Independently Predict the SSRIs Treatment in the Chinese Han Population

Abstract

Objective:

This study was intended to explore the relationship between the genetic polymorphisms of the 8 single nucleotide polymorphisms (SNPs) at CYP genes, neuroendocrine factors and the response to selective serotonin reuptake inhibitors (SSRIs) in Chinese Han depressive patients.

Method:

This was a 6-week randomized controlled trial consisting of 290 Chinese Han depressive patients treated with SSRIs. 8 SNPs of CYP450 genes and 7 neuroendocrine factors were detected. Allele and genotype frequencies were compared between responders and non-responders. The relationships between neuroendocrine factors and treatment response were also analyzed.

Results:

No significant differences were found in clinical features between 2 groups at the baseline. No statistical correlation was found between either the genotype or allele frequencies of SNPs in CYP1A2, CYP2C19, or CYP2D6 gene and the ­efficacy of SSRIs. There were strong linkage disequilibria between rs4986894, rs1853205, and rs12767583 of CYP2C19 genes, and rs2472299, rs2472300 of CYP1A2 genes. No associations were found between the above haplotypes and the antidepressant response. No neuroendocrine factor was a significant predictor for a response to SSRI antidepressants independently. The combination of neuroendocrine factors, however, predicted the response by 76.1%.

Conclusion:

There were no significant associations between the 6 SNPs of CYP gene polymorphisms and SSRI response. Neither cytochrome P450 family genes nor neuroendocrine factors independently predict the patients’ response to the antidepressants separately. A combination of neuroendocrine factors, however, does have the potential to predict the response.

Key words

major depressive disorder - CYP2D6 - CYP2C19 - CYP2C9 - CYP1A2 - pharmacogenetics - neuroendocrine factors

• References

• 1 World Health Organization . The World Health Report 1999. Geneva: WHO; 2000: 98-109
• 2 Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3: e442
• 3 Murray CJ, Lopez AD. Evidence-based health policy – lessons from the Global Burden of Disease Study. Science 1996; 274: 740-743
• 4 Horstmanna S, Binder EB. Pharmacogenomics of antidepressant drugs. Pharmacol Therap 2009; 124: 57-73
• 5 Trivedi MH, Rush AJ, Wisniewski SR et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163: 28-40
• 6 Duval F, Lebowitz BD, Macher JP. Treatments in depression. Pharmacol aspects 2006; 8: 191-206
• 7 Porcelli S, Drago A, Fabbri C et al. Pharmacogenetics of antidepressant response. J Psychiatry Neurosci 2011; 36: 87-113
• 8 Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry 2010; 15: 473-500
• 9 Sundberg MI, Sim SC, Gomez A et al. Influence of cytochrome P450 polymorphisms on drug therapies: Pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Therapeut 2007; 116: 496-526
• 10 Frodl T, Moller HJ, Meisenzahl E. Neuroimaging genetics: new perspectives in research on major depression?. Acta Psychiatr Scand 2008; 118: 363-372
• 11 Tomalik-Scharte D, Lazar A, Fuhr U et al. The clinical role of genetic polymorphisms in drug-metabolizing enzymes. Pharmacogenomics J 2008; 8: 4-15
• 12 Kirchheiner J, Nickchen K, Bauer M et al. Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol Psychiatry 2004; 9: 442-473
• 13 Serretti A, Calati R, Massat I et al. Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients. Int Clin Psychopharmacol 2009; 24: 250-256
• 14 Sistonen J, Fuselli S, Palo UJ et al. Pharmacogenetic variation at CYP2C9, CYP2C19, and CYP2D6 at global and microgeographic scales. Pharmacogenet Genomics 2009; 19: 170-179
• 15 Wang LL, Li Y, Zhou SF. A bioinformatics approach for the phenotype prediction of nonsynonymous single nucleotide polymorphisms in human cytochromes P450. Am Soc Pharmacol Exp Therapeut 2009; 37: 977-991
• 16 Bondy B. Pharmacogenomics in depression and antidepressants. Dialogues Clin Neurosci 2005; 7: 223-230
• 17 Lindpaintner K. Pharmacogenetics and pharmacogenomics in drug discovery and development: an overview. Clin Chem Lab Med 2003; 41: 398-410
• 18 Licinio J, Wong ML. The pharmacogenomics of depression. Pharmacogenomics J 2001; 1: 175-177
• 19 De Leon J, Susce MT, Murray-Carmichael E. The AmpliChip CYP450 genotyping test: integrating a new clinical tool. Mol Diagn Ther 2006; 10: 135-151
• 20 De Leon J. AmpliChip CYP450 Test: personalized medicine has arrived in psychiatry. Expert Rev Mol Diagn 2006; 6: 277-286
• 21 Zackrisson AL, Lindblom B, Ahlner J. High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultra rapid metabolism among suicide cases. Clin Pharmacol Ther 2010; 88: 354-359
• 22 Peters EJ, Slager SL, Kraft JB et al. Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. PLoS One 2008; 3: e1872
• 23 Suzuki Y, Sawamura K, Someya T. Polymorphisms in the 5-hydroxytryptamine 2A receptor and cytochromeP4502D6 genes synergistically predict fluvoxamine-induced side effects in Japanese depressed patients. Neuropsychopharmacology 2006; 31: 825-831
• 24 Grasmader K, Verwohlt PL, Rietschel M et al. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. Eur J Clin Pharmacol 2004; 60: 329-336
• 25 Rau T, Wohlleben G, Wuttke H et al. CYP2D6 genotype: impact on adverse effects and nonresponse during treatment with antidepressants – a pilot study. Clin Pharmacol Ther 2004; 75: 386-393
• 26 Charlier C, Broly F, Lhermitte M et al. Polymorphisms in the CYP2D6 gene: association with plasma concentrations of fluoxetine and paroxetine. Ther Drug Monit 2003; 25: 738-742
• 27 Murphy GM, Remer C, Rodrigues HE et al. Pharmacogenetics of antidepressant medication intolerance. Am J Psychiatry 2003; 160: 1830-1835
• 28 Ohara K, Tanabu S, Ishibashi K et al. CYP2D6*10 alleles do not determine plasma fluvoxamine concentration/dose ratio in Japanese subjects. Eur J Clin Pharmacol 2003; 58: 659-661
• 29 Gerstenberg G, Aoshima T, Fukasawa T et al. Relationship between clinical effects of fluvoxamine and the steady-state plasma concentrations of fluvoxamine and its major metabolite fluvoxamino acid in Japanese depressed patients. Psychopharmacology 2003; 167: 443-448
• 30 Yin OQ, Wing YK, Cheung Y et al. Phenotype-genotype relationship and clinical effects of citalopram in Chinese patients. J Clin Psychopharmacol 2006; 26: 367-372
• 31 Duval F, Mokrani MC, Monreal Ortiz JA et al. Cortisol hypersecretion in unipolar major depression with melancholic and psychotic features: dopaminergic, noradrenergic and thyroid correlates [J]. Psychoneuroendocrinology 2006; 31: 876-888
• 32 Min W, Liu C, Yang Y et al. Alterations in hypothalamic-pituitary-adrenal/thyroid (HPA/HPT) axes correlated with the clinical manifestations of depression. Prog Neuro-Psychopharmacol Biol Psychiatry 2012; 39: 206-211
• 33 Zhang M. The handbook for psychiatric assessment [M]. Changsha: Hunan science and technology press; 1998: 121-133
• 34 Cha PC, Mushiroda T, Takahashi A et al. Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. Hum Mol Genet 2010; 19: 4735-4744
• 35 Teichert M, Eijgelsheim M, Rivadeneira F et al. A genome-wide association study of acenocoumarol maintenance dosage. Hum Mol Genet 2009; 18: 3758-3768
• 36 Shi YY, He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res 2005; 15: 97-98
• 37 Barrett JC, Fry B, Maller J et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005; 21: 263-265
• 38 Li Z, Zhang Z, He Z et al. A partition-ligation-combination-subdivision EM algorithm for haplotype inference with multiallelic markers: update of the SHEsis. (http://analysis.bio-x.cn). Cell Res 2009; 19: 519-523
• 39 Arzu G, Gul O, Elif HV et al. Influence of genetic polymorphisms, smoking, gender and age on CYP1A2 activity in a Turkish population. Pharmcogenomics 2009; 10: 769-778
• 40 Dobrinas M, Cornuz J, Oneda B et al. Impact of smoking, smoking cessation, and genetic polymorphisms on CYP1A2 activity and inducibility. Clin Pharmacol Ther 2011; 90: 117-125
• 41 Sullivan PF, Neale MC, Kendler KS. Genetic epidemiology of major depression: review and meta-analysis. Am J Psychiatry 2000; 157: 1552-1562
• 42 Lotrich FE. Gene-environment interactions in geriatric depression. Psychiatr Clin North Am 2011; 34: 357-376
• 43 aan het Rot M, Mathew SJ, Charney DS. Neurobiological mechanisms in major depressive disorder. CMAJ 2009; 180: 305-313